In the morning of January 8th, the 2018 National Science and Technology Award Ceremony was solemnly held in the Great Hall of People in Beijing. The project of President Professor Li Xiaokun’s team, “Key Technological Breakthroughs, Theoretical Innovation and Industrialization of China’s Original Cell Growth Factor Protein Drugs” , won the second prize of the National Science and Technology Progress Award.
After 30 years of exploration and practice, Professor Li Xiaokun’s research team focused on the theoretical innovation and technological breakthroughs in the common technical problems of the clinical transformation and pharmaceutical development of fibroblast growth factor drugs. The team carried on systematic and in-depth research on the optimization of process technology, the development of new protein preparations, establishment of long-term modification technology, expansion of indications and identification of new mechanisms and new functions, and many innovative achievements have been achieved, which greatly improves the applicable population and patient compliance, and significantly improves the competitiveness and market share of Chinese growth factor drugs. This forms a new theory of independent innovative drug research and promotion in China, and establishes China’s international position of growth factor drugs industrialization.
With the increasing number of diabetic patients, the number of patients with foot ulcers and ocular surface ulcers and dry eyes increased. According to the report of the Annual Conference of Diabetic Peripheral Vascular Disease and Podiatry of Chinese Medical Association in 2017, diabetes can lead to multiple organ damage in the whole body, among which the incidence of diabetic foot is 8.1%, amputation rate is 27.3%, and mortality rate being as high as 40% within 5 years after amputation. In the past 10 years, Professor Li’s team has systematically upgraded the innovative drug development system of growth factor in terms of new problems, new characteristics and new demands of clinical trauma treatment with the ideas of transformational medicine and integrated medicine. The team excavated new mechanisms and targets from the theoretical point of view, expanded the types of preparations and scope of indications from the application level, which benefit the patients with amputations and blindness caused by the chronic ulcers. The team develops 3 level-1 growth factor drugs, 1 category III implantable medical devices, cultivates 4 drugs with annual sales exceeding 100 billion yuan, obtains 9 clinical instructions and authorized invention patents of 45. The whole series of growth factor drugs has been applied in 5500 hospitals in China with 68 million clinical drug users. The team published 96 high-level SCI papers in Nature and other journals, and those papers have been cited 1946 times by Nature and other journals. Their research has formed a new drug development and clinical transformation model based on the important clinical needs, which is closely integrated by schools, enterprises and doctors. It provides practical basis and theoretical support for the sustainable development of recombinant protein drugs in China.
This award-winning project’s completion persons are Li Xiaokun, Wang Xiaojie, Huang Zhifeng, Lin Li, Xiao Jian, Huang Yadong, Hui Qi, Fang Haizhou and Song Lihua. Project completion organizations are Wenzhou Medical University, Zhuhai Essex Bio-Pharmaceutical Company, Anhui Anke Biotechnology Group and Guangzhou Jinan University Biopharmaceutical R&D Center.
In the past 3 years, Wenzhou Medical University has seized the development opportunities to vigorously implement the innovation-driven strategy, adhere to double-wheel drive of scientific and technological innovation and institutional mechanism innovation, strengthen the training of key scientific research talents, construct the academic innovation team, advocate the cross-integration of fundamental and clinical medicine, and strengthen the exchanges and cooperation with high-level scientific research institutions at home and abroad. The above actions have constantly improved the level of scientific and technological innovation of the University. Among the years, 3 national research platforms including national key laboratory, national international science and technology cooperation base and province-ministry joint collaborative innovation center have been approved; 13 major national projects have been approved, and the number of National Natural Science Foundation projects is among the top 2 among provincial universities; 1 project won the 2nd prize of National Science and Technology Progress Award, 34 research awards won at provincial and ministerial levels; in 2018, the university first publish paper in Nature as the first author affiliation.